Denosumab
-
Subject Areas on Research
- 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
- An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer.
- Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management.
- Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.
- Denosumab for the treatment of osteoporosis.
- Development, reliability, and validity of a new Preference and Satisfaction Questionnaire.
- New and emerging therapies for bone metastases in genitourinary cancers.
- Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines.
- Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.
- Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study.
- Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass.
- Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States.
- c-ANCA vasculitis after initiation of denosumab.